Samant Hrishikesh, Manatsathit Wuttiporn, Dies David, Shokouh-Amiri Hosein, Zibari Gazi, Boktor Moheb, Alexander Jonathan Steve
Division of Gastroenterology and Hepatology, Department of medicine, LSU health, Shreveport, LA 71103, United States.
Division of Gastroenterology and Hepatology, University of Nebraska, Omaha, NE 68194, United States.
World J Clin Cases. 2019 Jul 6;7(13):1571-1581. doi: 10.12998/wjcc.v7.i13.1571.
Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease. Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid (UDCA), the current standard treatment for cholestatic liver disease. Important novel treatment targets now also include nuclear receptors involved in bile acid (BA) homoeostasis like farnesoid X receptor and G protein-coupled receptors ., the G-protein-coupled BA receptor "transmembrane G coupled receptor 5". Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA. In this review, we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.
最近，胆汁淤积领域有了极大的扩展，这反映出人们对胆汁分泌及其在慢性胆汁淤积性疾病中受到干扰的分子机制有了更深入的了解。对于对熊去氧胆酸（UDCA）反应不佳的患者，已经开发出了新的抗胆汁淤积治疗方案，UDCA是目前胆汁淤积性肝病的标准治疗药物。现在重要的新治疗靶点还包括参与胆汁酸（BA）稳态的核受体，如法尼醇X受体和G蛋白偶联受体，即G蛋白偶联BA受体“跨膜G偶联受体5”。成纤维细胞生长因子-19和肠肝循环BA转运体作为额外的药物靶点也值得关注，潜在治疗药物norUDCA也是如此。在这篇综述中，我们讨论了胆汁淤积性肝病中近期和未来有前景的治疗药物及其潜在的分子机制。
